selected publications
- The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. Nature. 2024 Academic Article GET IT
- Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
- Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER). BMC cancer. 2023 Academic Article GET IT
- Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Academic Article GET IT
- Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy. The Prostate. 2023 Academic Article GET IT
-
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.
European urology.
2023
Letter
GET IT
Times cited: 1 - Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial. BMJ open. 2022 Academic Article GET IT
- Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
- The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Molecular oncology. 2022 Academic Article GET IT
- Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. British journal of cancer. 2022 Academic Article GET IT
- Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer. 2021 Academic Article GET IT
- Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. The oncologist. 2021 Academic Article GET IT
- A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clinical genitourinary cancer. 2021 Academic Article GET IT
-
A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
European urology.
2021
Academic Article
GET IT
Times cited: 2 -
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC).
Cancer.
2021
Academic Article
GET IT
Times cited: 41 -
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer.
Frontiers in oncology.
2021
Academic Article
GET IT
Times cited: 31 -
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
The Prostate.
2021
Academic Article
GET IT
Times cited: 15 -
Common germline-somatic variant interactions in advanced urothelial cancer.
Nature communications.
2020
Academic Article
GET IT
Times cited: 23 -
Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
JCO oncology practice.
2020
Information Resource
GET IT
Times cited: 39 -
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.
Cancer.
2020
Academic Article
GET IT
Times cited: 30 -
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer.
Urologic oncology.
2020
Academic Article
GET IT
Times cited: 9 -
Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Clinical genitourinary cancer.
2020
Academic Article
GET IT
Times cited: 5 -
Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
Clinical genitourinary cancer.
2020
Academic Article
GET IT
Times cited: 8 -
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177 Lu-J591) for Metastatic Castration-Resistant Prostate Cancer.
The oncologist.
2020
Academic Article
GET IT
Times cited: 27 -
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
Investigational new drugs.
2020
Academic Article
GET IT
Times cited: 4 -
Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1α-Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma.
Translational oncology.
2019
Academic Article
GET IT
Times cited: 27 -
Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.
PloS one.
2019
Academic Article
GET IT
Times cited: 12 -
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.
JCO precision oncology.
2019
Academic Article
GET IT
Times cited: 33 -
Clinical features of neuroendocrine prostate cancer.
European journal of cancer.
2019
Academic Article
GET IT
Times cited: 217 -
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
Nature communications.
2019
Academic Article
GET IT
Times cited: 155 -
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.
Cancer.
2019
Academic Article
GET IT
Times cited: 33 -
Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 46 -
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
European journal of cancer.
2018
Academic Article
GET IT
Times cited: 31 -
A multidisciplinary approach for the management of earlier stage renal cell carcinoma.
Urologic oncology.
2018
Information Resource
GET IT
Times cited: 2 -
Recommendations for the Management of Rare Kidney Cancers.
European urology.
2017
Information Resource
GET IT
Times cited: 28 -
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.
JCO precision oncology.
2017
Academic Article
GET IT
Times cited: 43 -
PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017
Editorial Article
GET IT
Times cited: 3 -
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Academic Article
GET IT
Times cited: 68 -
Clonal evolution of chemotherapy-resistant urothelial carcinoma.
Nature genetics.
2016
Academic Article
GET IT
Times cited: 231 - Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Editorial Article GET IT
-
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
The oncologist.
2016
Academic Article
GET IT
Times cited: 86 -
Recent advances in the management of renal cell carcinoma.
F1000Research.
2016
Information Resource
GET IT
Times cited: 5 -
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma.
The Journal of clinical endocrinology and metabolism.
2016
Academic Article
GET IT
Times cited: 12 -
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
Cancer chemotherapy and pharmacology.
2015
Academic Article
GET IT
Times cited: 48 -
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
The Lancet. Oncology.
2015
Academic Article
GET IT
Times cited: 511 -
Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy.
Critical reviews in oncology/hematology.
2015
Information Resource
GET IT
Times cited: 29 -
Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.
Frontiers in oncology.
2015
Information Resource
GET IT
Times cited: 34 -
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis.
Clinical genitourinary cancer.
2014
Academic Article
GET IT
Times cited: 30 -
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
Annals of oncology : official journal of the European Society for Medical Oncology.
2014
Academic Article
GET IT
Times cited: 73 -
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).
Cancer chemotherapy and pharmacology.
2013
Academic Article
GET IT
Times cited: 85 -
Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials.
European journal of cancer.
2013
Academic Article
GET IT
Times cited: 60 -
Long-term response to sunitinib therapy for metastatic renal cell carcinoma.
Clinical genitourinary cancer.
2013
Academic Article
GET IT
Times cited: 54 -
Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression.
Oncogene.
2012
Academic Article
GET IT
Times cited: 117 -
Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.
American journal of clinical oncology.
2011
Academic Article
GET IT
Times cited: 73 -
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
Cancer.
2011
Academic Article
GET IT
Times cited: 104 -
mTOR inhibitors in advanced renal cell carcinoma.
Hematology/oncology clinics of North America.
2011
Review
GET IT
Times cited: 103 -
Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow.
The oncologist.
2011
Information Resource
GET IT
Times cited: 70 -
Genomic deregulation during metastasis of renal cell carcinoma implements a myofibroblast-like program of gene expression.
Cancer research.
2010
Academic Article
GET IT
Times cited: 30 -
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
Investigational new drugs.
2010
Academic Article
GET IT
Times cited: 81 -
Targeting renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Editorial Article
GET IT
Times cited: 53 -
Rare T-cell lymphomas.
Cancer treatment and research.
2008
Article
GET IT
Times cited: 1